Drug General Information |
Drug ID |
D0D3WR
|
Former ID |
DNC005425
|
Drug Name |
9-benzyl-6-(furan-2-yl)-9H-purin-2-amine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C16H13N5O
|
Canonical SMILES |
C1=CC=C(C=C1)CN2C=NC3=C(N=C(N=C32)N)C4=CC=CO4
|
InChI |
1S/C16H13N5O/c17-16-19-13(12-7-4-8-22-12)14-15(20-16)21(10-18-14)9-11-5-2-1-3-6-11/h1-8,10H,9H2,(H2,17,19,20)
|
InChIKey |
FZKKCBUDFSOYPA-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Adenosine A1 receptor |
Target Info |
Inhibitor |
[1]
|
Adenosine A2a receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
cAMP signaling pathway
|
Sphingolipid signaling pathway
|
Neuroactive ligand-receptor interaction
|
Morphine addictionhsa04015:Rap1 signaling pathway
|
Calcium signaling pathway
|
Vascular smooth muscle contraction
|
Parkinson's disease
|
Alcoholism
|
NetPath Pathway
|
TCR Signaling Pathway
|
RANKL Signaling Pathway
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
Reactome
|
Adenosine P1 receptors
|
G alpha (i) signalling eventsR-HSA-187024:NGF-independant TRKA activation
|
G alpha (s) signalling events
|
Surfactant metabolism
|
WikiPathways
|
Nucleotide GPCRs
|
GPCRs, Class A Rhodopsin-like
|
GPCR ligand binding
|
GPCR downstream signalingWP80:Nucleotide GPCRs
|
Monoamine Transport
|
NGF signalling via TRKA from the plasma membrane
|
GPCR downstream signaling
|
GPCRs, Other
|
References |
REF 1 | Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. Epub 2008 Mar 30.Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidinesand 6-arylpurines. |